Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359231160140
Abstract: Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific… read more here.
Keywords: tebentafusp; first class; tebentafusp first; treatment ... See more keywords